Clinical trial information: NCT04935359.doi:10.1200/JCO.2022.40.16_suppl.TPS4193Eileen Mary O'ReillyTalia GolanMasafumi IkedaMichele MilellaJulien TaiebZev A. WainbergLi-Wei WangNana GyambibiEva Maria Lopez-MartinKun XuAmerican Society of Clinical OncologyJournal of Clinical Oncology...
Conclusions: Data showing target engagement and TGF-β pathway inhibition supported the proof of mechanism of NIS793. The RDE of the combination was established and well tolerated in pts with advanced solid tumors. Clinical trial information: NCT02947165. 展开 ...
Clinical trial information: NCT04935359 .doi:10.1200/JCO.2023.41.4_suppl.TPS767Zev A. WainbergTeresa MacarullaTalia GolanMasafumi IkedaMichele MilellaJulien TaiebLiwei WangNana GyambibiEva M. LópezAna Bento Pereira da SilvaAmerican Society of Clinical Oncology (ASCO)Journal of Clinical Oncology...